Transfer factor in chronic mucocutaneous candidiasis

Biotherapy

Volumn 9, Issue 1-3, 1996, Pages 97-103

  Masi, Massimo ^a,b   De Vinci, Caterina ^b   Baricordi, Olavio Roberta ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Candida albicans; candidiasis; cell mediated immunodeficiency; chronic mucocutaneous candidiasis; transfer factor

Indexed keywords

CANDIDA ANTIGEN; HLA ANTIGEN; TRANSFER FACTOR;

ADOLESCENT; ADULT; BLOOD DONOR; CANDIDA ALBICANS; CELLULAR IMMUNODEFICIENCY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SPECIFICITY; FEMALE; HUMAN; HUMAN CELL; INFECTION; LEUKOCYTE MIGRATION; LYMPHOBLASTOID CELL LINE; LYMPHOCYTE TRANSFORMATION TEST; MALE; MUCOCUTANEOUS CANDIDIASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0029730253     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02628665     Document Type: Conference Paper

References (18)

1. Rosen FS, Wedgwood RJ, Eibl M, Griscelli C.SeUgman M, Aiuti F, Kishimoto T, Matsumoto S, Khakhalin LN, Hanson LA, Hitzig WH, Thompson RA, Cooper MD, Good RA & Waldmann TA. Report of a meeting held on September 4, 1991 at Tomamu, Hokkaido, Japan. In: Rosen FS, Seligman M. eds. Immunodeficiencies. Harwood Academic Publishers GmbH, 1993.
2. Luzi G, Businco L & Aiuti F. Primary immunodeficiency syndromes in Italy: A report of the National Register in children and adults. J Clin Imm 1983; 3: 4.
3. Levin AS, Spitler LE, Sûtes DP, Fudenberg HH.WiskottAldrich syndrome, a genetically determined cellular immunologie deficiency: Clinical and laboratory responses to therapy with transfer factor. Proc Acad Sei, 1970; 67: 821-28.
4. Kirkpatrick CH & Greenberg LE. Treatment of chronic mucucutaneous candidiasis with transfer factor. In: Khan A, Kirkpatrick CH, Hill NO, eds. Immune Regulators in transfer factor. New York: Academic Press, 1983: 547-62.
5. Littman BH, Rocklin RE, Parkman R & David JR.Transfer factor treatment of chronic mucocutaneous candidiasis: requirement for donor reactivity to Candida antigen. Clin Imm Im 1978; 9:97-105.
6. Rosenfeld F, Viza D, Phillips J, Vjch JM, Binet O.AronBrunetiere R. Traitement des infections herpétiques par le facteur de transfert. Presse Méd 1984; 13: 537-40.
7. Viza D, Rosenfeld F, Phillips J, Vich JM, Denis J.Bonissent JF & Dogbe K. Specific bovine transfer factor for the treatment of herpes infections. In: Kirkpatrick CH, Burger DR, Lawrence HS, eds. Immunobiology of transfer factor. New York: Academic Press, 1983; 245-59.
8. Viza D, Vich JM, Phillips J & Rosenfeld F. Orally administered specific transfer factor for the treatment of herpes infections. Lymphok Res 1985; 4: 27-30.
9. Viza D, Vich JM, Phillips J & Davies DAL. Use of specific transfer factor for the prevention or the treatment of herpes infections in mice and in man. J Exp Path 1987; 3:407-20.
10. Viza D, Vieh JM, Phillips J, Rosenfeld F & Davies DAL. Spécifie transfer factor protects mice against lethal challenge with herpes simplex virus. Cell Immun 1986; 100: 555-62.
11. PizzaG,VizaD,AblashiDV,JeromeL,ArmstrongG&Levine PH. The possible use of specific transfer factor in the treatment of patients with nasopharyngeal carcinoma. In: Grundman E, Krueger GRF, Ablashi DV, eds, Nasopharyngeal Carcinoma. Stuttgart: Fisher- Verlag Editor, 1981: 301-7.
12. Levine PH, Pizza G, Cannon G, Ablashi DV, Armstrong G & Viza D. Cell-mediated immunity to Epstein-Barr virusassociated membrane antigens in patients with nasopharyngeal carcinoma. In: Grundman E, Krueger GRF, Ablashi DV, eds, Nasopharyngeal Carcinoma. Stuttgart: Fisher-Verlag Editor, 1981: 137-44.
13. Viza D, Goust JM, Moulias R, Trejdosiewicz LK, Collard A & Mueller-Bérat N. In vitro production of transfer factor by lymphoblastoid cell lines. Transplan P 1975; VII (suppl.l): 329-33.
14. Viza D, Boucheix Cl, Césarini JP, Ablashi DV, Armstrong G, Levine PH & Pizza G. Characterization of a human lymphoblastoid cell line, LDV/7, used to replicate transfer factor and immune RNA. Bio Cell 1982; 46: 1-10.
15. Centifanto YP, Zam ZS, McNeil JL & Kaufman HE. Leukocytes migration inhibitory factor in HSV infections. Inv Ophth V 1978; 17: 863-68.
16. S0berg M & Bendixen G. Human lymphocyte migrations a parameter of hypersensitivity. Acta Med Scand 1967; 181: 247-53.
17. Pizza G, Severini G, Menniti D, De Vinci C & Corrado F. Tumour regression after intralesional injection of Interleukin2 (IL2) in bladder cancer. Preliminary report. Int J Cane 1984; 34: 359-67.
18. Inostroza J, Munoz P, Espinoza R, Millaqueo L, Diaz P, Leiva L & Sorensen R. Quantitation of soluble class I heterodimers and beta 2- microglobulin in patients with active pulmonary tuberculosis. Human Immun 1994; 40: 179-82.